Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News eFFECTOR Therapeutics Inc (EM) EFTR

Healthcare Biotechnology
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company’s lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (EXPM:EFTR)

LightWave Acquisition Corp. Announces Closing of $215,625,000 Initial Public Offering, Including Full Exercise of Underwriters' Over-Allotment Option

GlobeNewswire June 26, 2025

LightWave Acquisition Corp. Announces Pricing of $187,500,000 Initial Public Offering

GlobeNewswire June 24, 2025

Kaskela Law LLC Announces Investigation of eFFECTOR Therapeutics, Inc. (EFTR) and Encourages Former eFFECTOR Employees to Contact the Firm

Newsfile July 15, 2024

eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq

GlobeNewswire June 24, 2024

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer

GlobeNewswire May 20, 2024

eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 9, 2024

eFFECTOR Therapeutics to Participate in Upcoming Investor Conference

GlobeNewswire April 9, 2024

eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

GlobeNewswire April 4, 2024

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 25, 2024
View More News ››

Opinion & Analysis (EXPM:EFTR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (EXPM:EFTR)

EFTR....darn near killed 'er! NR this a.m....crash

  eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non...
Iseneschal - April 4, 2024
View more Bullboard ››

Lithium Ionic Corp

Lithium Ionic Corp

Lithium Ionic Corp., together with its subsidiaries, engages in the acquisition, exploration, and development of lithium ...
View More »